Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny pacjenta (ECOG 0-1)
- •Potwierdzona diagnoza zaawansowanego lub rozprzestrzenienia się nowotworu
- •Wcześniejsze leczenie standardowe
- •Potwierdzony brak białka MTAP w guzie
- •Prawidłowa funkcja wątroby
- •Prawidłowa funkcja nerek
- •Pisemna zgodę na udział w badaniu
✗ Disqualifies
- •Alergia lub nietolerancja badanego leku lub pembrolizumabu
- •Niekontrolowana choroba towarzysząca utrudniająca udział w badaniu
- •Aktywny zakażenie wymagające leczenia
- •Udział w innym badaniu klinicznym
- •Zaburzenia wchłaniania w przewodzie pokarmowym
- •Aktywny nowotwór w innej lokalizacji
- •Przerzuty do mózgu z objawami neurologicznymi
- •Aktywna choroba wątroby z innego powodu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (26)
Stanford University
Palo Alto, United States
Grand Valley Oncology
Grand Junction, United States
Florida Cancer Specialists & Research Institute
Lake Mary, United States
Sylvester Comprehensive Cancer Center
Miami, United States
University Chicago Medicine
Chicago, United States
Carle Cancer Center
Urbana, United States
Midwestern Regional Medical Center, City of Hope Chicago
Zion, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Henry Ford Cancer Center
Detroit, United States
New York University Langone Health
New York, United States
Sarah Cannon Tennessee Oncology
Nashville, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
Next Oncology Virginia
Fairfax, United States
CHU de Brest
Brest, France
Centre Berard Leon
Lyon, France
Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS
Saint-Herblain, France
Institute Gustav Roussy
Villejuif, France
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
Hospital HM Nou Delfos
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital de Sanchinarro
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Trial contact
Maxim Pimpkin, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.